A Study of the Effectiveness and Safety of Lanreotide Autogel/ Depot for Patients who have Lung Neuroendocrine Tumors

Overview

Información sobre este estudio

The purpose of this study is to evaluate the effectiveness and safety of lanreotide acetate analog/ depot plus the best standard care for the treatment of lung neuroendocrine tumors that have spread or can not be surgically removed.

Elegibilidad para la participación

Los requisitos de elegibilidad de los participantes incluyen la edad, el sexo, el tipo y el estadio de la enfermedad, y los problemas de salud o tratamientos previos. Las pautas difieren de un estudio a otro e identifican quiénes pueden o no pueden participar. No hay garantía de que cada persona elegible que desee participar en un ensayo se inscribirá. Comunícate con el equipo del estudio para analizar la elegibilidad del estudio y la posible participación.

Inclusion Criteria

  • Has metastatic and/or unresectable pathologically confirmed well-differentiated, typical or atypical neuroendocrine tumor of the lung
  • Histologic evidence of well differentiated neuroendocrine tumors (NETs) of the lung (typical and atypical according to the World Health Organisation (WHO criteria), evaluated locally)
  • Has a mitotic index < 2 mitoses/2 mm2 for typical carcinoid and < 10 mitoses/2 mm2 and/or foci of necrosis for atypical carcinoid
  • At least one measurable lesion of the disease on CT or MRI imaging RECIST 1.1
  • Positive Somatostatin receptors imaging

Exclusion Criteria

  • Poorly differentiated or high grade carcinoma, or neuroendocrine tumors not of lung origin
  • Has been treated with an Somatostatin analog at any time prior to randomization, except if that treatment was for less than 15 days (e.g. peri-operatively) of a short acting SSA or one dose of a long acting SSA and the treatment was received more than 6 weeks prior to randomization
  • Has been treated with Peptide receptor radionuclide therapy (PRRT) at any time prior to randomization
  • Has been treated with more than one course of cytotoxic chemotherapy or molecular targeted therapy or interferon for Lung NET

Sedes participantes de Mayo Clinic

Los estatus de los estudios cambian con frecuencia. Comunícate con el equipo del estudio para obtener la información más actualizada acerca de la posibilidad de participar.

Sede de Mayo Clinic Estatus Contacto

Rochester, Minn.

Investigador principal de Mayo Clinic

Thorvardur Halfdanarson, M.D.

Cerrado para la inscripción

Contact information:

Cancer Center Clinical Trials Referral Office

855-776-0015

More information

Publicaciones

Publications are currently not available
.
CLS-20260191

Mayo Clinic Footer